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For decades, ascorbic acid (aka vitamin C), has been popularly 
prescribed by alternative and complementary health care practi-
tioners and used by individuals or patients with various health 
conditions, including cancer progression [1], due to its renowned 
antioxidant property [2], which consists to neutralize free radicals 
such as superoxide (H2O2) and hydroxyl (OH) radicals, as well as 
its capacity to protect and repair normal cells that are damaged by 
chemotherapy or radiation therapy [3]. Surprisingly, the mecha-
nism of  anti-tumor effect of  ascorbic acid, especially used at high 
dose, has been proposed to be mediated by generation of  H2O2 
and secondary metabolite[4].
Interestingly, a number of  studies have reported the benefits of  
ascorbic acid in preventing and treating cancers [5]. Thereby, in 
some preclinical studies led in-vitro and in-vivo, ascorbic acid in-
duced tumor cells apoptosis and even enhanced the anti-tumor 
effects of  chemotherapy [6-7], acting then as a potentially good 
therapeutic adjuvant. Conversely, evidence from other studies and 
randomized trials[8] suggested that ascorbic acid during chemo-
therapy or radiation therapy may protect tumor cells and reduce 
the treatment efficacy.
Besides, a meta-analysis published this year and which aimed to 
associate dietary ascorbic acid supplement intake and survival in 
breast cancer patients, showed that the relative risk (RR) of  breast 
cancer-specific mortality can be lowered with 100 mg intake per 
day of  ascorbic acid, [9]. However, it is important to point out the 
fact that the experimental conditions of  the studies used in this 
meta-analysis differed notably in terms of  dosage, formulation 
and administration type and schedule, causing these confounders 
difficult to control. Besides, it is noteworthy that in sub-analy-
sis of  Women’s Health Initiative (WHI) study, dietary intake of  
ascorbic acid was not associated with a reduction in ovarian can-
cer risk [10].
Therefore, the challenging issues still concern: (i) which dose 
(high or low) and administration setting are really beneficial for a 
patient suffering from cancer? (ii) which cancer is prone to ascor-
bic acid therapy based on efficacy/toxicity risk ratio? (iii) which 
are the fully clear molecular mechanisms mediated by ascorbic 
acid in cancers?; (iv) which are the benefits or risks of  using nano 
encapsulated ascorbic acid, considering the systemic bioavailabil-
ity of  such compound?; (v) which are the benefits or risks of  
combining (nano-)ascorbic acid with (nano-) anti-cancer agents 
(chemical drugs and/or bio therapeutics)?
In light of  these few observations from inconsistent studies, it 
is difficult to state that ascorbic acid is an anti-cancer agent, and 
many issues still need to be accurately and promptly addressed 
first from a holistic point of  view before prescribing it in a per-
sonalized manner. Ongoing studies certainly provide new inter-
esting insights about ascorbic acid effects on cancers.
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